Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
A new publication in Blood Cancer Journal 24 February 2017, PMID: 28234347
Primary Authors: Shweta Chavan, Ph.D., and Brian Walker, Ph.D.
Targeted gene sequencing was conducted on 578 cases of plasma cell neoplasms, including monoclonal gammopathy of undermined significance (MGUS), smoldering myeloma and myeloma, in order to identify prognostic markers and treatment targets. A clinically certified, commercially available gene profiling panel, FoundationOneHeme – known as F1H – was used. The F1H test is aimed at identifying genetic abnormalities for which targeted treatments are available. Out of the 578 cases, 331, or 64 percent, were found to have potentially targetable alterations. The study also confirmed an important role for bi-allelic inactivation of key genes in myeloma at relapse and that loss of one of those genes, RB1, is an independent prognostic marker.
An allele is a variant form of a gene. Some genes have a variety of different forms, which are located at the same position, or genetic locus, on a chromosome. Humans are called diploid organisms because they have two alleles at each genetic locus, with one allele inherited from each parent.
The RB1 gene provides instructions for making a protein called pRB. This protein acts as a tumor suppressor, which means that it regulates cell growth and keeps cells from dividing too fast or in an uncontrolled way.
Extensive remineralization of large pelvic lytic lesions following total therapy treatment in patients with multiple myeloma
A new publication in Journal of Bone and Mineral Research
27 February 2017, PMID: 28240368
Primary Authors: Meera Mohan, M.D., and Maurizio Zangari, M.D.
Bone lesions — caused by the imbalances between bone formation and bone resorption — are a hallmark of multiple myeloma bone disease. Patients with bone lesions of the pelvis are at increased risk for fracture and related complications and frequently require surgical intervention. After observing unexpected radiological improvement in a patient whose treatment included the proteasome inhibitor bortezomib, a retrospective analysis of 62 patients treated with combination therapy was conducted. Forty-three percent of the patients experienced remineralization of the pelvic lesions. The study showed that significant mineral deposition in large pelvic lesions can be re-established in a significant proportion of myeloma patients treated on one of the Myeloma Institute’s multi-agent regimens. These findings can impact future quality-of-life treatment strategies.
A proteasome inhibitor is a drug that blocks the action of proteasomes — large protein complexes that help destroy other cellular proteins when they are no longer needed.
The Myeloma Institute is a trailblazer in the development of innovative treatments for myeloma and other plasma cell neoplasms. With a firm commitment to helping patients regain their lives and look forward to a disease-free future, the institute’s health care team provides expertise while extending compassion and encouragement.
Patients and families frequently ask how they can give back to the Myeloma Institute as a gesture of gratitude and as a way to support future patients.
For many, regardless of financial capacity, the answer is a planned gift. This giving mechanism can take many forms. For example, it can be stipulated in a will as a future gift, it can be set up as an annuity that provides current income, or it can be in the form of an endowment, such as an endowed chair in honor of a professor or program. A planned gift can sometimes provide relief from certain taxes.
A planned gift is an excellent way to solidify philanthropic intent and provide resources for generations to come.
If you are interested in finding out more about planned giving, please contact Tom Stephenson, senior director of development for the Myeloma Institute at 501-526-6990, extension 8551, or TLStephenson@uams.edu. Information about planned giving can also be found on the UAMS website at www.giftplanning.uams.edu.
In thinking of legacy, we hope you consider the Myeloma Institute as a worthy recipient of your generosity.
Ambassador Ruth A. Davis traveled the world as a diplomat during her 40 years with the U.S. Foreign Service.
But when she learned she had a relapse of multiple myeloma, she headed to Arkansas and the UAMS Myeloma Institute.
“I’ve often had people ask me, ‘Why don’t you go somewhere in the area, closer to home.’ I tell them, ‘Listen. This is a question of my life and I will go where the best treatment is available,’” she said during a recent visit to UAMS.
Davis, who lives in Washington, D.C., has been receiving treatment at the Myeloma Institute for a decade. She was first diagnosed with multiple myeloma in 2000 and was told she could expect to live three years.
When she relapsed, she decide to come to the Myeloma Institute at the recommendation of a friend.
“My experience with UAMS has been wonderful,” Davis said. “It has exceeded my expectations. The staff is accommodating. There is a community that has been developed to assist the patients of UAMS. They’re welcoming and competent. It gives me the confidence I need to proceed with fighting this disease.”
A trailblazer throughout her 40 years with the Foreign Service, Davis says she enjoyed every minute of it. She was the first African-American director of the U.S. Foreign Service Institute, and the first African-American woman to be director general of the Foreign Service. In 2016 she became the first African-American to receive the American Foreign Service Association’s Lifetime Contribution to American Diplomacy Award.
Beyond her world travels, Davis is proud to be an official Arkansas Traveler — a designation bestowed upon her by the governor. She is usually accompanied on her trips to Little Rock by her sister Eugenia Davis-Clements. The two women love meeting new people at UAMS and in the community and are known by many for their smiles and upbeat attitudes.
While Davis says having multiple myeloma and going through treatments has slowed her down a bit, she does not let it stop her. In November 2016 she traveled to Europe twice: to Brussels to chair the conference of the International Women’s Entrepreneurial Challenge and then to Vienna for the 50th anniversary of the United Nations Development Organization.
Davis is under the care of Frits van Rhee, M.D., Ph.D., professor in the UAMS College of Medicine and director of developmental and translational medicine at the UAMS Myeloma Institute.
“I feel that I get the individual attention that I need. I’m not just a case study. I’m a patient with a real need and he is responsive to that. He’s one of the best in the business so I’m delighted to be a patient of Dr. van Rhee. And I am truly grateful to be patient at the Myeloma Institute.”
How do new patients find their way to the Myeloma Institute? Often through a family physician or local oncologist or through a lot of online research. Sometimes the path is a bit circuitous. That was the case for Linda King from Lee’s Summit, Missouri.
In 2006 Linda received the devastating news of her diagnosis, thanks to her family physician’s insistence that they figure out the cause of Linda’s anemia that surfaced during a routine physical exam. He referred her to a cancer center for more diagnostic testing. With confirmation from results of a bone marrow biopsy and the pronouncement of an average life expectancy of three years from a Kansas City oncologist, Linda and her husband, Steve, was back in her family doctor’s office asking for a second opinion. At his suggestion, they made an appointment at MD Anderson Cancer Center in Houston.
Then, some unexpected networking kicked in. A lifetime friend of Steve’s, who lives 1,300 miles away, shared Linda’s diagnosis with a golfing partner, who happens to be an oncologist. The oncologist encouraged Steve’s friend to tell Linda that she should go to the Myeloma Institute at UAMS “because it is the best place in the world to receive treatment for multiple myeloma.”
Still pondering their options, Linda and Steve met with the oncologist who had treated Steve’s father for lymphoma. That oncologist recommended canceling the MD Anderson appointment and going directly to Little Rock because the Myeloma Institute focused almost exclusively on myeloma and was, in his opinion, the best at fighting it.
Two separate oncologists — from different parts of the country — made the same recommendation. That was enough for Linda and Steve to finalize a decision about where to go for treatment.
When Linda first came to the Myeloma Institute she was gripped by fear — fear that cancer could not be controlled and that the treatment would be grueling.
“Our world was full of unknowns, and frankly we were scared to death to leave our home and go to Little Rock to learn more about what to expect from this cancer,” Steve said.
Linda was enrolled in the Total Therapy III protocol that included two back-to-back stem cell transplants — one in August 2006 and the second in October 2006 — as well as chemotherapy during the induction and consolidation phases of treatments. She has been in complete remission ever since.
The most challenging aspects of treatment for Linda were the fatigue and separation from family, friends, and home. Her antidote to the challenges and the fear was a positive attitude fueled by her own inner strength, a dream to see her great-grandchildren enter the world one day, and reassurance from her Myeloma Institute physician that she had an excellent chance of a normal life expectancy.
The rewards for Linda are many, as she is able to live life the way she wants without any limitations from the myeloma or the treatments. The ultimate reward, in addition to sustained complete remission, is that she got to welcome great-grandchildren into the family. Linda spends a lot of time with them and is an integral part of their lives.
“If we had to do it again, we would definitely opt to come to the Myeloma Institute in a heartbeat,” she said.
Many patients who travel to the Myeloma Institute discover that Little Rock is filled with warm hospitality and an abundance of interesting sites, such as the River Market, the William J. Clinton Presidential Center
and the Old State House.
“We found various special things in and around Little Rock that actually made our trips enjoyable,” Linda said. “Steve is an avid bicycle rider and the Arkansas River Trail is one of the best off-road biking/walking trails he has ever experienced. He takes his bike on every trip to Little Rock.”
Linda and Steve are grateful to the Myeloma Institute for enabling Linda to live life in a totally productive and enjoyable way. That gratitude has led them to make annual donations in support of the institute’s research.
“We anticipate that you compete with other, more common cancers, for research dollars. We hope that, in some small way, we are helping you to help others, just like you did for us,” they said. “We would advise anyone who has been diagnosed with myeloma to make sure that the Myeloma Institute is on the list of choices to consider. And then move it to the top of that list.”